AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been approved in the US for the treatment of adult patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR)

Monopar Therapeutics Inc., a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced the successful dosing of the first patient in its open-label Phase

Veralox Therapeutics, a clinical-stage biotechnology company developing first-in-class therapies targeting the 12-lipoxygenase (12-LOX) pathway, announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to VLX-1005, a small molecule 12-LOX

Concept Matrix Solutions, Inc. or the a privately held vertically integrated biotechnology company dedicated to developing and manufacturing innovative delivery forms in both pharmaceutical and nutraceutical spaces today announced that it has received patent

Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for treatment of life-threatening pulmonary diseases, today announced

Eclipse Life Sciences, Inc., a privately held clinical-stage biopharmaceutical company focused on the development of novel therapies for ophthalmic diseases, today announced that it has enrolled

Palisade Bio, Inc., a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases

Crinetics Pharmaceuticals, Inc., announced the launch of the ACRO/TRUTH healthcare provider (HCP) educational website and initiative, the purpose of which is to spotlight

WestGene Biopharma is proud to announce that its mRNA therapeutic cancer vaccine, WGc-043, has received dual IND approvals from China's National Medical Products